Four notes:
1. Robotic pull-through, product launches, a resurgence in the biologic business, and competitive recruiting contributed to growth in the first quarter, the company said in a May 4 news release.
2. First-quarter net income was $45.3 million, a 74.7 percent year-over-increase from $25.9 million in the first quarter of 2020.
3. CEO Dave Demski said “enabling technologies revenue increased 86 percent, as surgeon recognition of the clinical superiority of our robotic technology produced back-to-back quarters of strong year-over-year growth.”
4. As of March 31, cash, cash equivalents and marketable securities were $838.4 million.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
